Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Advancing Therapy with iGlarLixi

Advancing Therapy with iGlarLixi

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Watch the video tackling the critical topic of dyslipidemia management post-acute coronary syndrome. Globally, despite its pivotal role in secondary prevention, the approach remains suboptimal, so we'll dissect Arafah MR et al recent publication, providing a detailed evaluation of lipid management after ACS in Saudi Arabia. Specifically, shining a spotlight on LDL-cholesterol management and delve into the complications of statin use in post-ACS Saudi patients.

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry

Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Achievement of lipid modification goals with Statins & Ezetimibe

Achievement of lipid modification goals with Statins & Ezetimibe

Single-Pill Combinations in Dyslipidemia

Single-Pill Combinations in Dyslipidemia

This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).

Management of ASMD - Expert opinion: Professor Moeen Al Sayed

Management of ASMD - Expert opinion: Professor Moeen Al Sayed

Professor Moeen gives a detailed explanation on how Olipudase Alfa acts in the body once administered.

Navigating the Pompe Disease Journey

Navigating the Pompe Disease Journey

Recognizing key signs and symptoms along the way

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Galimberti F, et al. Poster presented at the 91st European Atherosclerosis Society congress (EAS) 2023.

Statin/ezetimibe SPC for better adherence to LLT

Statin/ezetimibe SPC for better adherence to LLT

This large cohort study of patients from the Lombardy region (Italy) demonstrated that the single-pill combination of statin and ezetimibe substantially improved adherence to drug therapy vs the two-pill combination of respective drugs.